secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001171843-22-003483
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q1 2022 net loss $51M; cash $263M; botensilimab to Phase 2; Gilead $5M milestone
--------------------------------------------------------------------------------

- Net loss of $51M ($0.19/share) vs $54M ($0.27/share) YoY; revenue $26M (up from $12M).
- Cash and short-term investments $263M, down from $307M at Dec 31, 2021; cash used in ops $52M.
- Botensilimab advancing to Phase 2 trials in colorectal, melanoma, pancreatic cancers; data in Q3 2022.
- AGEN1571 (ILT2) Phase 1 to start; AGEN2373 milestone of $5M from Gilead (up to $570M potential).
- Cost containment measures initiated to reduce operating expenses in coming quarters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/0001171843-22-003483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/f8k_051022.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-003483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer